Ace Therapeutics is committed to maximizing the therapeutic efficacy of oligonucleotide drugs in liver disease. Therefore, we are deeply involved in oligonucleotide-targeted liver delivery and aim to provide the most professional and comprehensive services to our customers worldwide.
Although aggregation in the liver is an inherent property of nucleotide drugs, targeting the liver alone is not sufficient for the treatment of liver disease. Enrichment in the liver alone rather than specifically in the lesion-associated hepatocytes also does not achieve the desired effect. Therefore, Ace Therapeutics offers comprehensive services for targeted liver delivery of oligonucleotides to clients worldwide. Our services cover different delivery systems to meet the different research needs of our clients.
What Can We Do?
Oligonucleotide Drug Delivery Development for The Treatment of Liver Disease
Accurate delivery of oligonucleotide drugs to the damaged areas of the liver enables them to achieve the most optimal effect. To further enhance the effectiveness of oligonucleotides in the treatment of liver disease, we offer a comprehensive range of oligonucleotide-specific drug delivery services.
- Chemical Methods for Enhanced Delivery
We will chemically modify the oligonucleotide drug so that the candidate oligonucleotide drug can reach the site of injury more consistently and effectively.
- Biological Methods for Enhanced Delivery
We offer high-qulity and comprehensive services to enhance oligonucleotide drug delivery targeting the liver by different biological means.
Conjugation is one of the main strategies to enhance oligonucleotide delivery. We have an extensive field in the conjugation of oligonucleotides and can provide you with the most professional advice and the most complete service.
Bioconjugation Oligonucleotide bioconjugation primarily facilitates the interaction between the conjugate and its corresponding cell surface receptor protein, leading to subsequent internalization via receptor-mediated endocytosis. Bioconjugates are usually small in size and usually exhibit favorable biodistribution characteristics.
GalNAc Conjugates GalNAc is a carbohydrate moiety that binds with high affinity to cumulonimbus protein receptor 1 (ASGR1, ASPGR), which is highly expressed in the liver. GalNA-conjugated ASO is preferentially delivered to hepatocytes in vivo, whereas unconjugated ASO is predominantly detected in non-parenchymal hepatocytes detected in them.
Antibody & Aptamer Conjugates Due to the specific interaction between antibodies and cell surface receptors, they are widely used as delivery vehicles for other types of drugs. Aptamers are considered "chemical antibodies" and are able to bind with high affinity to their respective target proteins.
Peptide Conjugates Peptides can impart therapeutic oligonucleotide couples with tissue/cell-targeting, cell-penetrating, or endosomolytic properties.
Lipid Conjugates Covalent conjugation to lipid molecules has been used to enhance the delivery of siRNA and antagonist ASOs. Cholesterol siRNA has been used for hepatic gene silencing
We have a dedicated team in the field of liposome and nanotechnology-based delivery system development and can provide you with efficient and high-quality services. Liposome technology and nanotechnology occupy an important position in the field of delivery systems due to their unique biophysical and biological properties. Common methods used for oligonucleotide drug delivery are endogenously derived exosomes, spherical nucleic acids, and self-assembled DNA nanostructures.
The dual blood supply of the liver and the unique structure of the hepatic sinusoid parenchyma allow for high transfection efficiency by systemic injection of AAV transduction.
Ace Therapeutics has accomplished many projects related to oligonucleotide drug delivery and has accumulated a lot of experience and know-how. We continue to optimize our technologies and methods to ensure the accuracy and scientific validity of our services. If you would like to learn more about our services, please feel free to contact us.
Reference
- Roberts, T. C., et al., Advances in oligonucleotide drug delivery. Nat Rev Drug Discov, 2020. 19(10): p. 673-694.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
